The program was equally safe with both procedures. Postoperative antithrombotic heparin does not appear necessary in low-risk patients. Bariatric surgical ERAS programs are evolving and not yet standardized.

Morbid obesity in adolescents has been treated effectively with laparoscopic adjustable gastric banding (LAGB). We prospectively studied 97 consecutive obese adolescents undergoing LAGB over the course of 10 years. The average patient age at surgery was 17.2 ± 0.7 years; mean body mass index, 44.9 ± 6.1 kg/m. Excluding those lost to follow-up (n = 21), respective mean total weight loss and excess weight loss were 20.0 ± 16.6 and 46.6 ± 39.5% (n = 76, 78.4%). An ascending trend line showed a significant positive correlation between excess weight loss and follow-up duration (mean 56.0 ± 22.0 months). There was no mortality or morbidity. Nineteen patients (25.0%) underwent band removal at a mean 43.0 ± 28.0 months. LAGB proved safe and effective over the mid- and longer term; it should be strongly considered as a procedure of first intention for obese adolescents.

“Enhanced recovery after surgery” (ERAS) protocols may reduce morbidity, length of hospital stay (LOS), and costs. During the 4-year evolution of a bariatric ERAS protocol, we found that administration of thrombophylaxis selectively to high-risk morbidly obese patients (assessed postoperatively by Caprini score ≥ 3) undergoing omega loop gastric bypass (“mini” gastric bypass) or sleeve gastrectomy resulted in safe outcomes. Both procedures proved equally effective with this protocol. The vast majority of rapidly mobilized, low-risk patients did not appear to require antithrombotic heparin. Similar to other reported ERAS outcomes, our recent year’s results in 485 patients included a mean LOS of 1.08 ± 0.64 days (range 1–14), with 460 (95.0%) discharged on day 1 and 99.6% by day 2. There were 13 30-day complications (2.7%), two reinterventions (0.4%), and no hemorrhages.